Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies

Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer

Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route

Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice

The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised „proof-of-principle“ phase II study

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells

Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells